Renal & Nephrology Pathways

16 pathways

Work through 16 interactive renal & nephrology decision pathways — branching, guideline-grounded workflows that take you from presentation to assessment, risk stratification and management. Each pathway cites its source (NICE, ESC, AHA and specialty guidance), embeds the relevant calculators, and makes escalation and safety-netting explicit. For decision support only — apply clinical judgement and local protocols.

Acute Kidney Injury (AKI)

KDIGO-based AKI assessment, staging, and management including nephrotoxin review and RRT indications

KDIGO 2012 / NICE AKI 2019
CKD Management

CKD staging, cardiovascular and renal risk reduction, anaemia, and referral thresholds

NICE CKD 2021 / KDIGO 2024
Nephrotic Syndrome

Diagnosis and management of nephrotic syndrome including biopsy indication and complication management

KDIGO 2021
RRT Initiation

Indications for renal replacement therapy and modality choice in AKI and CKD

KDIGO 2012 / NICE
Acute Pyelonephritis

Acute Pyelonephritis clinical pathway.

NICE; BAUS; RCOG — CG109, NG109
Glomerulonephritis Workup

KDIGO 2021 — recognise nephritic syndrome, RPGN red flags, immunology screen, biopsy indications, treatment of pauci-immune / anti-GBM / lupus / IgA / post-infectious.

KDIGO 2021 GN; Renal Association
Chronic Hyperkalaemia Management

Long-term management in CKD/HF — dietary, drugs, potassium binders to enable RAAS continuation.

Renal Association 2020; NICE TAs
Hyponatraemia Workup

European guidelines — assess severity + symptoms, classify by volume status + urine osmolality + sodium, avoid rapid correction (osmotic demyelination).

European Hyponatraemia Guidelines 2014; Renal Association
Hypercalcaemia (Adult)

Differentiate parathyroid vs malignancy, IV fluids + bisphosphonates, denosumab, treat cause.

Society for Endocrinology; NICE NG12
CKD-Mineral Bone Disease (CKD-MBD)

KDIGO 2017 — assess Ca, phosphate, PTH, vitamin D, vascular calcification; phosphate binders, vitamin D analogues, calcimimetic, parathyroidectomy.

KDIGO 2017 CKD-MBD
Renal Transplant Rejection

Recognise acute rejection — biopsy diagnosis (cellular vs antibody-mediated), treatment, infection prophylaxis.

KDIGO 2009 Transplant; BTS 2024
Lupus Nephritis

Class III/IV (proliferative) and class V (membranous) — induction with MMF or cyclophosphamide, maintenance, hydroxychloroquine, belimumab/voclosporin.

EULAR/ERA-EDTA 2019; KDIGO 2024
Diabetic Nephropathy

Annual albuminuria screen, RAAS blockade, SGLT2i + finerenone, glycaemic + BP optimisation, plan for renal replacement.

KDIGO 2022 Diabetes; NICE NG28; ADA 2024
Autosomal Dominant Polycystic Kidney Disease

Diagnosis (Pei-Ravine criteria), risk stratification (Mayo class), tolvaptan, cardiovascular & extra-renal complications.

KDIGO 2024; UK Kidney Association 2024
Renal Artery Stenosis

Recognise FMD vs atherosclerotic, role of revascularisation (CORAL trial), medical therapy.

ESC 2018; ACC/AHA 2024
Membranous Nephropathy

Anti-PLA2R, primary vs secondary, KDIGO risk-based therapy (rituximab/cyclophosphamide+steroid/calcineurin inhibitor).

KDIGO 2021 GN